PIOS (Patras Immunotherapy Score) Score Is Associated with Best Overall Response, Progression-Free Survival, and Post-Immunotherapy Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) Treated with Anti-Program Cell Death-1 (PD-1) Inhibitors

Immunotherapy with immune checkpoint inhibitors (ICIs) has changed the therapeutic management of advanced non-small cell lung cancer (aNSCLC) over the last decade. However, there is an unmet need for clinically useful biomarkers in this patient subgroup. The aim of this study was to combine baseline...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimitrakopoulos, Foteinos-Ioannis, Nikolakopoulos, Achilleas, Kottorou, Anastasia, Kalofonou, Fotini, Liolis, Elias, Frantzi, Theodora, Pyrousis, Ioannis, Koutras, Angelos, Makatsoris, Thomas, Kalofonos, Haralabos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280986/
https://www.ncbi.nlm.nih.gov/pubmed/32429368
http://dx.doi.org/10.3390/cancers12051257

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7280986/
https://www.ncbi.nlm.nih.gov/pubmed/32429368
http://dx.doi.org/10.3390/cancers12051257

Ejemplares similares